Ryan Suplee, MD
Vascular Surgery · Sarasota, FLNPI 1013232289
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,000 of the $63,862 with a category attached, or 61.1%. Alphatec Spine, Inc accounts for 83.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $29,116 and has fallen 68.3% since, to $9,241 in 2025. Among vascular surgery clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $271.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alphatec Spine, Inc$53K
- Silk Road Medical, Inc.$2K
- W. L. Gore & Associates, Inc.$2K
- Medtronic$2K
- Penumbra, Inc.$1K
- Boston Scientific$1K
- plus $3K from 17 others
What the payments were for
- Consulting fees$39,00061%
- Travel & lodging$15,45524%
- Food & beverage$9,40615%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alphatec Spine, Inc | 32 | $53,278 |
| Silk Road Medical, Inc. | 27 | $2,397 |
| W. L. Gore & Associates, Inc. | 26 | $1,640 |
| Medtronic(3 entities) | 37 | $1,585 |
| Penumbra, Inc. | 26 | $1,175 |
| Boston Scientific | 27 | $1,134 |
| Globus Medical | 6 | $692 |
| Philips North America LLC | 20 | $611 |
| Cvrx, Inc. | 7 | $549 |
| Abbott | 2 | $171 |
| Inari Medical, Inc. | 5 | $105 |
| Smith+Nephew | 5 | $98 |
| Cardiovascular Systems Inc. | 1 | $83 |
| Tactile Systems Technology Inc | 3 | $78 |
| Angiodynamics, Inc. | 1 | $42 |
| Inspiremd Ltd | 1 | $41 |
| Stryker | 2 | $39 |
| Johnson & Johnson | 1 | $32 |
| Cashflow Solutions, LLC | 2 | $29 |
| Mimedx Group, Inc. | 1 | $23 |
| Aroa Biosurgery Incorporated | 1 | $23 |
| Polymedics Innovations Inc. | 1 | $19 |
| Lemaitre Vascular, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solus ALIF$35,312
- Other - Miscellaneous$16,690
- ENROUTE Transcarotid Neuroprotection System$1,994
- ENROUTE Transcarotid Stent$1,187
- ENHANCE Transcarotid Peripheral Access Kit$773
- ENROUTE Transcarotid Stent System$640
- ENROUTE 0.014 Guidewire$640
- Endurant$622
- ALIF$611
- Indigo System$522
- ELUVIA$493
- Barostim Neo System$472
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$288
- IdentiTi$203
- GORE TAG Conformable Thoracic Endoprosthesis$179
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$168
- RUBY Coil$140
- VIABAHN Endoprosthesis with Heparin Bioactive Surface$136
- ENROUTE .014 Guidewire$134
- Labosys$128
How this compares
$63,862 in reported general payments places this provider in the 90th percentile of 385 vascular surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $131,288 |
| XareltoRivaroxaban | 17 | $23,679 |
| ClopidogrelClopidogrel Bisulfate | 276 | $2,189 |
| Gabapentin | 30 | $233 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 26 | $202 |
| Cilostazol | 14 | $183 |
| Atorvastatin Calcium | 24 | $111 |
| Furosemide | 11 | $6 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $32 | $23,67917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 385 vascular surgery providers in Florida.
Other vascular surgery in Sarasota
- Inkyong ParrackSarasota$80K
- Jason WagnerSarasota$62K
- Russell SamsonSarasota$43K
- Samuel TapperStuart$1.3M
- Mariano ArosemenaBradenton$472K
- Manuel Perez IzquierdoOrlando$302K
- Erin MooreJacksonville$300K
- Rajesh MalikNaples$237K
- Charles BaileyTampa$162K
- Joseph WasselleMelbourne$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.